Objective: Relapse is still the most important cause of death all over the world, and approximately 15-20% of children experience a recurrence of the disease. Material and Methods: Among 474 patients who received their first treatment from December 2012 to March 2024 at pediatric hematology oncology clinic, 48 patients who relapsed were included in the study. Diagnosis of initial and relapse acute lymphoblastic leukemia was made by morphological and immunophenotypic evaluation of bone marrow and other samples, and the patients were treated with Berlin-Frankfurt-Munster protocols. The risk of recurrence, T-cell bone marrow relapse, very early relapse, early bone marrow relapse, recurrence after bone marrow transplantation, t(9;22) and t(1;19) positive were defined as “high-risk”; the others as “standard-risk”. Results: Thirty four (71%) of the cases were male, 32 (67%) were bone marrow 4 (8%) were isolated central nervous system (CNS), 5 (10%) were bone marrow + CNS, 7 (17%) were other sites, 27 (44%) were highrisk, and 8 (21%) allogeneic transplants were performed. The calculated 86-month overall survival rate is 51%. The event-free survival (EFS) is 62% at 96 months in standard-risk and 36% at 61 months in high-risk (p=0.037). It is 38% at 37 months after relapse. Furthermore, EFS 53% at 49 months for isolated bone marrow recurrence and 31% at 14 months for recurrence at other sites (p=0.481). Also, it is 25% at 14 months, which is considered very early according to the time of recurrence, 36% in the last 16 months, and 81% EFS at 73 months (p=0.02). Conclusion: Although follow-up periods are relatively short, our overall and EFS is comparable to that of developed countries. The risk situation and the time of recurrence are the most important factors affecting the outcome. Contrary to expectations, isolated bone marrow recurrences had a better EFS rate, suggesting that the lack of statistical difference is because of the low number of isolated non-bone marrow recurrence cases.